## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no full-text methods, figures, or statistical details were available for evaluation
- **Shared manuscript claim summary** The authors propose that PRDM5 is a shared susceptibility gene for atherosclerotic cardiovascular disease (ASCVD), acting through transcriptional regulation of ASK1 to drive macrophage inflammation, lipid accumulation, and apoptosis, with downstream endothelial dysfunction via paracrine effects, and that ezetimibe suppresses PRDM5 transcriptional activity
- **Visible evidence base** Multi-trait GWAS via Genomic SEM, TWAS in CD14+ monocytes, expression validation in clinical samples, cellular functional assays, ChIP-qPCR, dual-luciferase reporter assay, molecular docking
- **Missing materials affecting confidence** Full methods, sample sizes, statistical thresholds, effect sizes, GWAS/TWAS cohort details, ChIP-qPCR and luciferase data, docking parameters, ezetimibe concentration and specificity controls, and any supplementary figures or tables

## Reviewer
- **Overall assessment** The abstract presents a coherent and potentially interesting hypothesis linking PRDM5 to ASCVD through a defined molecular pathway. However, the evidence base as described is insufficient to establish the central claims. Key issues include lack of quantitative data, unclear statistical rigor for the genetic analyses, and absence of experimental controls or specificity tests for the proposed mechanism. The therapeutic claim regarding ezetimibe is particularly under-supported.
- **Who would be interested in the results, and why** Researchers in atherosclerosis genetics, macrophage biology, and vascular inflammation would find the proposed PRDM5-ASK1 axis relevant. Clinicians interested in repurposing ezetimibe for anti-inflammatory effects may also take note, though the current evidence is preliminary.
- **Major strengths** The use of multi-trait GWAS and TWAS to prioritize a candidate gene is a modern and appropriate approach. The combination of genetic, transcriptomic, and functional validation in a single study is ambitious. The focus on shared pathogenic mechanisms across vascular territories addresses an important clinical gap.
- **Major Concerns** See detailed items below.
- **Minor Comments** See detailed items below.
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3, R1-M4
- **Assessment against Nature-style criteria** Originality is moderate; the PRDM5-ASK1 link is novel but the pathway (JNK/NF-kappaB) is well-trodden. Scientific importance is potentially high if the genetic evidence is robust, but this is not verifiable from the abstract. Interdisciplinary readership is plausible, but the abstract lacks sufficient detail for nonspecialists to assess the genetic methodology. Technical soundness cannot be evaluated without full data. Readability for nonspecialists is acceptable but would benefit from clearer definitions of key terms.
- **Recommendation posture** Currently not established from the provided evidence. Supportive if technical concerns are resolved with full data and appropriate controls.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Statistical rigor and genetic evidence
- **Claim pointer** "PRDM5 was identified as a pivotal ASCVD risk gene" based on multi-trait GWAS and TWAS
- **Evidence pointer** Methods section, "Multi-trait GWAS datasets were analyzed via Genomic SEM" and "TWAS was performed in CD14(+) monocytes"
- **Concern** The abstract does not report any quantitative metrics for the genetic analyses, such as genome-wide significance thresholds, effect sizes, or false discovery rates. It is unclear whether PRDM5 reached significance after multiple testing correction in either the Genomic SEM or TWAS framework.
- **Why it matters** Without these metrics, the claim that PRDM5 is a "pivotal" risk gene cannot be distinguished from a chance finding or a weak association. The entire study hinges on this genetic prioritization step.
- **Resolution test** Provide the specific p-values, effect sizes, and correction methods for the PRDM5 locus in both the multi-trait GWAS and TWAS analyses. State the sample sizes and ancestry of the cohorts.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Mechanistic evidence and specificity
- **Claim pointer** "PRDM5 directly binds the ASK1 promoter to trigger ASK1/JNK/NF-kappaB signaling"
- **Evidence pointer** Methods section, "ChIP-qPCR, dual-luciferase reporter assay"
- **Concern** The abstract does not provide any data on the magnitude of PRDM5 binding to the ASK1 promoter, the specific binding region, or whether this binding is functionally required for ASK1 transcription. No loss-of-function or rescue experiments are described to establish causality.
- **Why it matters** Direct binding alone does not prove transcriptional regulation. Without showing that PRDM5 knockdown or overexpression alters ASK1 expression and downstream signaling in a manner dependent on the identified binding site, the mechanistic claim remains correlative.
- **Resolution test** Include ChIP-qPCR enrichment values with appropriate controls, luciferase reporter activity with and without PRDM5 perturbation, and rescue experiments with ASK1 overexpression or a promoter mutant.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Therapeutic claim
- **Claim pointer** "Ezetimibe suppresses the transcriptional activity of PRDM5"
- **Evidence pointer** Methods section, "molecular docking" and "ezetimibe-mediated therapeutic effects"
- **Concern** The abstract does not specify the concentration of ezetimibe used, the cell types tested, or whether the effect is specific to PRDM5. Molecular docking alone is predictive and does not demonstrate functional suppression. No in vivo or clinical validation is mentioned.
- **Why it matters** The therapeutic implication is a major selling point of the study. If the ezetimibe effect is not dose-dependent, specific, or reproducible, the claim could mislead clinical interpretation.
- **Resolution test** Provide dose-response curves for ezetimibe on PRDM5 transcriptional activity, a negative control compound, and validation in primary macrophages or an animal model.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** Yes
- **Axis** Functional phenotype integration
- **Claim pointer** "aggravating macrophage lipid overloading, inflammatory activation and apoptosis, and further inducing endothelial dysfunction through paracrine mediators"
- **Evidence pointer** Methods section, "Cellular functional assays"
- **Concern** The abstract lists multiple phenotypic outcomes but provides no quantitative readouts, such as lipid content measurements, cytokine levels, apoptosis rates, or endothelial dysfunction markers. It is unclear whether these effects are independent or sequential, and whether they are all mediated by the ASK1/JNK/NF-kappaB pathway.
- **Why it matters** The claim of a shared pathogenic mechanism requires that the same pathway drives all these phenotypes. Without data showing that pathway inhibition reverses each phenotype, the integration is speculative.
- **Resolution test** Present quantitative data for each phenotype with and without PRDM5 modulation and with and without ASK1/JNK/NF-kappaB inhibition.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity of terminology
- **Affected element** "shared genetic susceptibility" and "common pathogenic factors"
- **Evidence pointer** Background section
- **Issue** The terms "shared" and "common" are used interchangeably but may imply different levels of genetic overlap across vascular territories. The abstract does not define the criteria for "shared."
- **Required correction** Define what constitutes a shared locus or factor, and specify the number of vascular territories analyzed.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Experimental design transparency
- **Affected element** "validated in clinical peripheral blood monocytes and atherosclerotic plaques"
- **Evidence pointer** Methods section
- **Issue** The abstract does not state the number of patients or controls, the source of plaque tissue, or whether the validation was quantitative (e.g., qPCR, Western blot) or qualitative.
- **Required correction** Provide sample sizes, tissue types, and the method of expression quantification.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Docking interpretation
- **Affected element** "molecular docking"
- **Evidence pointer** Methods section
- **Issue** Docking results are not described, including the predicted binding affinity or the binding site on PRDM5. Without this, the relevance of docking to the ezetimibe effect is unclear.
- **Required correction** Report docking scores and the predicted interaction residues, and clarify whether docking was used to predict binding or to rationalize functional data.

## Risk / unsupported claims
- The claim that PRDM5 is a "pivotal ASCVD risk gene" is unsupported without statistical metrics from the GWAS and TWAS.
- The claim that PRDM5 "directly binds" the ASK1 promoter is unsupported without ChIP-qPCR enrichment data and functional validation.
- The claim that ezetimibe suppresses PRDM5 transcriptional activity is unsupported without dose-response and specificity data.
- The claim that PRDM5 drives all listed macrophage phenotypes and endothelial dysfunction is unsupported without quantitative phenotype data and pathway inhibition experiments.
- The generalizability of findings to "multi-territory atherosclerosis" is not assessable from the abstract, as no territorial-specific data are presented.